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Summary 
Intercellular adhesion molecules play an important 
role in the generation of T lymphocyte-mediated im- 
mune responses. Here, we describe a novel accessory 
molecule, DNAX accessory molecule-1 (DNAM-1), that 
is constitutively expressed on the majority of periph- 
eral blood T lymphocytes. DNAM-1 is a 65 kDa trans- 
membrane glycoprotein consisting of 318 aa includ- 
ing two immunoglobulin-like domains. Anti-DNAM-1 
monoclonal antibody (MAb) inhibits T and NK cell- 
mediated cytotoxicity against a variety of tumor cell 
targets and blocks cytokine production by aUoanti- 
gen-specific T cells. In addition, DNAM-1 is a tyrosine- 
phosphorylated signal-transducing molecule that 
participates in primary adhesion during cytotoxic T 
lymphocyte (CTL)-mediated cytotoxicity. 
Introduction 
T lymphocyte-mediated cytotoxicity is a complex pro- 
cess involving engagement of the CD3-T cell antigen 
receptor complex (TCR), signal transduction, and sub- 
sequent cytolysis of target cells (Apasov et al., 1993; 
Berke, 1994, 1995; Henkart, 1994). In addition to specific 
antigen recognition by the TCR, cytotoxic T lympho- 
cytes (CTLs) require the engagement of intercellular ac- 
cessory molecules on T cells by their respective ligands 
expressed on target cells (Springer, 1990; Phillips et al., 
1991; O'Rourke and Mescher, 1992; Rodrigues et al., 
1992). A variety of accessory molecules expressed on 
T cells (including CD8, CD4, CD28, LFA-1, and CD2) are 
involved in this process (Bierer et al., 1989; Janeway, 
1988; Kupfer and Singer, 1989; Springer et al., 1987; 
Dustin and Springer, 1989; Kishimoto et al., 1987; Vives, 
1994). Accessory molecules facilitate the intercellular 
conjugation of CTL with target cells and transduce sig- 
nals that augment or synergize with signals from the 
TCR (Bierer et al., 1989; Springer, 1990). 
The adhesion molecules LFA-1 and CD2 are crucial 
for cytotoxicity mediated by many CTLs (Shaw et al., 
1986; Springer, 1990). CTL-mediated cytotoxicity, how- 
ever, is often not completely blocked in the presence 
of anti-CD2 or anti-LFA-1 monoclonal antibody (MAb) 
(unpublished data), suggesting the existence of other 
adhesion molecule(s) on CTL that are involved in the 
cytolytic process. In the present investigation, we have 
identified a novel signal-transducing adhesion mole- 
cule, DNAM-1, that is involved in cytotoxicity and lym- 
phokine secretion mediated by CTL. Here, we describe 
the functional and molecular characteristics of DNAM-I. 
Results 
DNAM-1 Is Involved in T Cell and NK 
Cell-Mediated Cytotoxicity 
Many CTL clones mediate "promiscuous" or natural 
killer (NK)-Iike lysis against a variety of tumor cell targets 
by an unknown mechanism that is independent of TCR 
engagement (TCR-independent cytotoxicity). To identify 
the accessory molecules involved in this process, we 
generated MAbs against a human CTL clone that inhib- 
ited TCR-independent cytotoxicity. The MAb DX11 was 
selected because of its ability to block cytotoxicity 
against a variety of tumor cell lines (Figure 1A). The 
antigen recognized by the DX11 MAb was designated 
DNAX accessory molecule-1 (DNAM-1). The DX11 MAb 
inhibited lysis of both hematopoietic and nonhemato- 
poietic target cells, but was selective in that anti-DNAM- 
1 did not affect killing of certain target cells (e.g., the 
JY and 721.221 Epstein-Barr virus [EBV]-transformed 
B lymphoblastoid cell lines) (Figure 1A). Since DNAM-1 
is expressed on the CTL but not on many of these tumor 
cell targets, these results indicated that DNAM-1 inhibits 
cytotoxicity at the level of the effector cell. Similar results 
were obtained when CTLs were precoated with DX11 
MAb and washed prior to the addition of the target cell 
lines (data not shown). DNAM-1 is also expressed on 
NK cell clones and F(ab')2 fragments of the DX11 MAb 
efficiently inhibited the NK cell-mediated cytotoxicity 
against these tumor cell targets, but did not affect cyto- 
toxicity against JY or 721.221 (Figure 1 B). 
DNAM-1 Expression on Hematopoietic Cells 
In peripheral blood, DNAM-1 is expressed on the major- 
ity of TCR~ ~ T cells, TCR~/~- T cells, NK cells (CD3 , 
CD56~), monocytes (CD14÷), and a subset of B cells 
(Figure 2), but is not on granulocytes or erythrocytes 
(data not shown). DNAM-1 is also expressed on a subset 
of thymocytes coexpressing high surface density CD3 
and on a variety of transformed hematopoietic cells 
(data not shown). DNAM-1, however, is not present on 
fibroblastic ell lines nor was it detected on tumor cell 
lines of epithelial or neuronal derivation (including the 
Colo-205 colon carcinoma cell line, the PA-1 ovarian 
teratocarcinoma cell line, the SK-N-SH neuroblastoma 
cell line, the MCF-7 breast carcinoma cell line, the 
BDMEL-1 melanoma cell line, and the CaOV3 ovarian 
carcinoma cell line). 
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Figure 1. Inhibition of CTL- and NK Cell-Mediated Cytolysis by Anti-DNAM-1 MAb, DXl~, 
(A) Anti-DNAM-1 MAb, DXl 1, and anti-CD18 (LFA-1 !3) MAb inhibit TCR-independent cytolysis against a variety of tumor cell targets mediated 
by CTL clones. Colo-205, PA-1, SK-N-SH, BDMEL-1, MCF-7, and CaOV3 are nonhematopoietic tumor cells lines and do not express DNAM- 
1. Hematopoietic cell lines tested include K562 (DNAM-1 negative), Jurkat (DNAM-1 positive), U937 (DNAM-1 negative), and the 721.221 and 
JY EBV-transformed B lymphoblastoid cell lines (both DNAM-1 positive). 
(B) DX11 MAb inhibits NK cell clone-mediated cytolysis against Colo-205, PA-1, and U937, but did not affect cytolysis of JY and 721.221. 
Data are representative of experiments using several CTL and NK clones. MAbs were used at 10 i~g/ml and the effector to target ratio was 
10:1. 
DNAM-1 Is Involved in the Antigen-Specif ic 
Cytotoxicity and Lymphokine Secretion 
Mediated by CTL 
HLA-A2-specific CD8 ~ CTL clones expressing cell sur- 
face DNAM-1 (Figure 3A) lysed the HLA-A2-expressing 
tumor lines JY and Colo-205 and cytotoxicity was com- 
pletely inhibited by anti-HLA-A2 or anti-CD3 MAbs. Ad- 
dition of the DX11 MAb to the cytotoxicity assays inhib- 
ited cytolysis of Colo-205, but had no effect on the 
cytolysis of JY (Figure 3B). Anti-CD18 MAb blocked allo- 
antigen-specific lysis of both Colo-205 and JY, demon- 
strating that LFA-1 is involved in cytotoxicity against 
both targets, whereas DNAM-1 is preferentially involved 
in killing of Colo-205 and not JY. 
Experiments were undertaken to determine whether 
DNAM-1 is also required for lymphokine secretion initi- 
ated by alloantigen recognition. DX11 MAb, as well as 
anti-CD18 or anti-HLA-A2 MAb, significantly inhibited 
the secretion of tumor necrosis factor-~ and interferon--y 
by the CTL cocultured with Colo-205 (Figure 3C). By 
contrast, the cytokine secretion by the CTL clones in- 
duced by JY was not inhibited by DX11 MAb. 
DNAM-1 Is a Signal-Transducing Molecule 
MAbs against CD2 and CD3 are able to trigger cytolytic 
activity when CTLs are cocultured with target cells ex- 
pressing Fc receptors (Spits et al., 1985; Mentzer et 
al., 1985; Siliciano et al., 1985; Scott et al., 1989). As 
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Figure 2. DNAM-1 Expression on Peripheral 
Blood Leukocytes 
DNAM-1 is expressed on CD3-CD4 T cells 
(90%), CD3~CD8 - T cells (80%), CD3~TCR-y5" 
T cells (99%), CD3 CD56 ÷ NK cells (97%), 
CD19 ÷ B cells (3%), and monocytes (100%) 
in peripheral blood. PBMCs from a healthy 
donor were stained with phycoerythrin 
(PE)-conjugated DX11, CyChrome-conju- 
gated anti-CD3, and FITC-conjugated anti- 
CD4, anti-CD8~x, anti-CD56, anti-CD19, or 
anti-CD14. The cells were analyzed by flow 
cytometry using a FACScan. An electronic 
gate was used to identify CD3 t (A) and CD3 
(B) lymphocytes and monocytes (C) and the 
FITC (x axis) and PE (y axis) fluorescence of 
these populations were displayed as contour 
plots (4 decade log scales), Greater than 98% 
of PBMCs stained with FITC-conjugated con- 
trol murine IgG1 and PE-conjugated control 
murine IgG were present in the lower left 
quadrant of the contour plots (data not 
shown). Data are representative of results ob- 
tained using several different blood donors. 
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demonstrated in Figure 4A, the DXl I MAb is also capa- 
ble of inducing antibody-mediated redirect cytolysis 
when CTLs are cocultured with the murine Fc receptor- 
bearing P815 mastocytoma. The magnitude of the anti- 
body-induced cytolysis was comparable to that ob- 
served with a MAb against CD3. In addition to enhancing 
conjugate formation between the CTL and P815 targets, 
DNAM-1 also appears to participate actively in signaling. 
As shown in Figure 4B, engagement of DNAM-1 by DXl 1 
MAb-coated P815 target cells resulted in tyrosine phos- 
phorylation of DNAM-1, with maximum phosphorylation 
occurring about 1 min after addition of the MAb. 
DNAM-1 Protein Purification and cDNA Cloning 
DNAM-1 protein was purified from lysates of peripheral 
blood mononuclear cells (PBMCs) using lectin affinity 
and DX11 MAb-affinity chromatography. The amino acid 
sequences of the N-terminal and three internal peptide 
(Figure 3 continued on next page) 
fragments were obtained from the purified DNAM-1 pro- 
tein (Figure 5A). Degenerate oligonucleotide primers 
were designed based on the N-terminal residues and 
an internal peptide residue and used to amplify a 100 
bp cDNA fragment from a T cell cDNA library. The 100 
bp fragment was then used as a probe to isolate a full- 
length DNAM-1 cDNA (Figure 5A). The DNAM-1 cDNA is 
2,603 bp and contains an open reading frame encoding 
a type 1 transmembrane protein with an 18 aa leader 
sequence, 230 aa extracellular domain, 28 aa transmem- 
brane domain, and 60 aa cytoplasmic region. Two pairs 
of cysteine residues in the extracellular domain were 
flanked by consensus sequences for immunoglobulin- 
like domains (Figure 5B), indicating that DNAM-1 is a 
member of the immunoglobulin supergene family. Three 
tyrosines are present in the cytoplasmic domain, and 
the REDIYNYP sequence may be phosphorylated by a 
src kinase (on the Y just down from the EDI) and is a 
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Figure 3. DNAM-1 Involvement inCytolysis and Lymphokine Secretion Mediated by Antigen-Specific CTL 
(A) DNAM-1 expression on an HLA-A2-specific CD8- CTL clone. Cells were stained with PE-conjugated DX11 MAb (shaded histogram) or PE- 
conjugated control IgG1 MAb (open histogram) and analyzed by flow cytometry. 
(B) DX11 MAb inhibited cytolysis of Colo-205, but not JY, mediated by HLA-A2-specific CTL clones AS547.97, AS547.93, and AS547.91. MAbs 
were used at 10 Fg/ml and the effector to target ratio was 5:1. 
(C) DX11 MAb inhibited the secretion of GM-CSF and tumor necrosis factor-c~ by HLA-A2-specific CTL clones AS547.97 and AS547.93 
stimulated by Colo-205, but not JY. MAbs were used at 10 t~g/ml. 
possible binding site for Grb2 (CanUey and Songyang, 
1994). Southern blot analysis of human genomic DNA 
suggests that DNAM-1 is encoded by a single gene (data 
not shown). The DNAM-1 gene is located on chromo- 
some 18q22.3, as determined by fluorescence in situ 
hybridization (Callen et al., 1990). DNAM-1 is unique, 
demonstrating no significant homology to other protein 
or nucleotide sequences in the GenBank, EMBL, or PIR 
databases. Although demonstrating only 22% homol- 
ogy, DNAM-1 is most similar to the tactile receptor 
(Wang et al., 1992) that is also expressed on CTL. 
The DNAM-1 cDNA was transfected into COS-7 cells, 
which resulted in surface expression of DNAM-1 protein 
as detected by immunofluorescence using the DX11 
MAb (Figure 5C). The molecular mass of DNAM-1 immu- 
noprecipitated from 1251-labeled lysates of both PBMC 
and COS-7 cells transfected with DNAM-1 cDNA was 
~65 kDa when analyzed by SDS-PAGE under both re- 
ducing and nonreducing conditions (Figure 5C). The mo- 
bility of DNAM-1 decreased from ~65 kDa to ,~35 kDa 
after treatment with N-glycosidase F (Figure 5D), consis- 
tent with the size of the polypeptide predicted from the 
DNAM-1 cDNA and the presence of 8 potential N-linked 
glycosylation sites in the extracellular domain (Fig- 
ure 5A). 
DNAM-1 Is an Adhesion Molecule 
The observation that DX11 MAb blocked CTL and NK 
lysis of some, but not all, targets suggested that certain 
cells may express cell surface ligands for DNAM-I. 
Therefore, experiments were performed to determine 
whether cells with a putative DNAM-1 ligand, such as 
Colo-205, would specifically adhere to COS-7 cells 
transfected with DNAM-1 cDNA. As shown in Figure 6, 
Colo-205 cells displayed significant binding to DNAM-1 ÷ 
COS-7 transfectants and this binding was specifically 
inhibited by the DX11 MAb. Visual examination of these 
cultures also indicated substantial clustering of Colo- 
205 to DNAM-1 transfected COS-7, but not to COS-7 
transfected with control gene (CD94) nor to untrans- 
fected COS-7 cells (data not shown). 
Discussion 
A successful strategy to identify membrane receptor on 
T lymphocytes involved in CTL function has been to 
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Figure 4. Signal Transduction via DNAM-1 
(A) An HLA-A2-specific CD8 ÷ CTL clone lysed murine FcR ~ P815 cells in the presence of DX11 MAb or anti-CD3 MAb, but not DX11 F(ab')2 
fragments. Data are representative of experiments performed with several CTL clones. MAbs were used at 10 Fg/ml. 
(B) HLA-A2-specific CTLs were stimulated with DXl 1 MAb-precoated P815 cells for the indicated time. Cells were then lysed and immunoprecipi- 
tated with control murine IgG1 MAb (clg), DXl I MAb, or anti-phosphotyrosine MAb (4G10). The immunoprecipitates were analyzed by Western 
blot using DX11 MAb, showing that tyrosine residues of DNAM-1 are phosphorylated after the stimulation. 
generate MAbs that block cytolysis. Using this ap- 
proach, LFA-1 (CD11aJCD18), CD2, and CD8 have been 
implicated as accessory molecules participating in cyto- 
lytic function (reviewed by Bierer and Burakoff, 1991; 
Berke, 1994). However, it is possible to generate CTL 
from patients lacking LFA-1 expression (van de Wiel- 
van Kemenade et al., 1992) and from mice with disrupted 
CD2 genes (Killeen et al., 1992). Also because MAbs 
against LFA-1, CD2, and CD8 often only partially block 
cytotoxicity, it seemed likely that other receptors in- 
volved in CTL function exist, prompting us to search for 
such molecules. DNAM-1 was identified by selecting a 
MAb that inhibits CTL and NK cell-mediated lysis. Like 
CD2 and LFA-1, DNAM-1 is expressed on most T and NK 
cells and functions as an intercellular adhesion molecule 
involved in cytolytic activity and lymphokine secretion. 
Functional studies suggest that the ligand for DNAM-1 
(DNAM-1 L) is a cell surface antigen broadly expressed 
on both hematopoietic and nonhematopoietic tissues. 
Similarly, the ligands for LFA-1, i.e., CD54 (Marlin and 
Springer, 1987; Rothlein et al., 1986), and CD2, i.e., CD58 
(Krensky et al., 1983; Dustin et al., 1987), are also ex- 
pressed on many cell types, allowing NK and T cells 
to interact with endothelial cells and epithelial tissues 
during immune responses. Further studies are underway 
to identify the DNAM-1L and determine the structural 
requirements involved in DNAM-1 binding. 
Because essentially all T and NK cells express LFA-1, 
CD2, and DNAM-1, the relative contribution of these 
receptors may depend upon the array and density of 
their ligands present on the antigen-presenting cells or 
target cells. In some situations, blocking any single re- 
ceptor-l igand interaction may only partially inhibit or fail 
to inhibit CTL function because other molecules are 
operational. Under other circumstances, the combina- 
tion of several receptors may be necessary to achieve 
the threshold of binding or signaling required to activate 
effector function, in which case blocking any one of 
several accessory molecules may be sufficient o inhibit 
cytotoxicity completely. The function of some adhesion 
molecules is affected by signals transmitted by the TCR. 
Dustin and Springer (1989) have shown that the affinity 
of LFA-1 for its ligand is transiently enhanced after TCR 
binding. Thus, the role of the various adhesion mole- 
cules in lymphocyte-antigen-presenting cell interac- 
tions may be dictated by a dynamic process and influ- 
enced by signals generated through other membrane 
receptors. 
Intercellular adhesion molecules provide not only for 
cell binding, but also participate in signal transduction. 
MAbs against CD2 function as agonists and can trigger 
CTL and NK cell cytolytic function (Siliciano et al., 1985). 
Similarly, cross-linking DNAM-1 with MAb induces cytol- 
ysis mediated by CTL and NK cells and also results 
in tyrosine phosphorylation of the DNAM-1 molecule. 
Presently, the tyrosine kinase responsible for DNAM-1 
phosphorylation is unknown and further studies are war- 
ranted to define the biochemical events accompanying 
DNAM-1 signal transduction. 
In summary, our studies have shown that DNAM-1 is 
a novel receptor involved in intercellular adhesion and 
lymphocyte signaling. Adhesion molecules play a critical 
role in a variety of immune responses including allograft 
rejection, tolerance (Isobe et al., 1992), cell differentia- 
tion (Gunji et al., 1992), lymphocyte homing (Hogg and 
Landis, 1993), and viral and tumor immunity (Springer, 
1990; Phillips et al., 1991). Since DNAM-1 is broadly 
expressed on a variety of peripheral eukocytes includ- 
ing T cells, NK cells, monocytes, and B cells, it may be 
involved in the wide range of immune responses. 
Experimental Procedures 
Hybridomas and Cell Lines 
The anti-DNAM-1 MAb DX11 (immunogiobulin G1 [IgG1], K) was 
generated by fusing the Sp2/0 myeloma cell lin  with splenocytes 
from a BALB/c mouse immunized with a human CTL clone. Hybrido- 
mas were cloned by using a FACStar (Becton Dickinson Immuno- 
cytometry Systems, San Jose, California). Colo-205 is a colon 
carcinoma cell ine, PA-1 is an ovarian teratocarcinoma cell line, 
SK-N-SH is a neuroblastoma cell line, MCF-7 is a breast carcinoma 
Immunity 
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Figure 5. Molecular Characteristics of 
DNAM-1 
(A) Nucleotide and predicted amino acid se- 
quences of DNAM-I. The leader and putative 
transmembrane domain are underlined. Pep- 
tide sequences that were obtained from puri- 
fied DNAM-1 protein are indicated by dotted 
underlines. Potential N-linked glycosylation 
sites in the extracellular domain and tyrosine 
phosphorylation sites in the cytoplasmic re- 
gion are circled and boxed, respectively. The 
GenBank accession number of DNAM-1 is 
U56102. 
(B) Schematic diagram of DNAM-1 protein. 
Leader peptide, extracellular, transmem- 
brane, and cytoplasmic regions are indicated. 
Two pairs of cysteine residues in the extracel- 
lular portion potentially able to participate in 
intrachain disulfide-bonding for the formation 
of immunoglobulin-like domains are indi- 
cated. 
(C) DNAM-1 expression on COS-7 cells 
transfected with pMET7 vector alone (open 
histogram) or with DNAM-1 cDNA in pMET7 
(shaded histogram). 
(D) 12~l-labeled COS-7 cells transfected with 
the DNAM-1 cDNA or PBMCs were lysed and 
DNAM-1 antigen was immunoprecipitated 
with control murine IgG1 or DX11 MAb. The 
immunoprecipitates were treated with N-gly- 
cosidase F, as indicated, and analyzed by 
SDS-PAGE. 
(Figure 5 continued on next page) 
cell line, K562 is an erythroleukemia cell line, Jurkat is a T cell 
leukemia cell line, U937 is a myeloid leukemia cell line, JY and 
721.221 are EBV-transformed B lymphoblastoid cell lines (American 
Type Culture Collection, Rocky\lie, Maryland). BDMEL-1 is a mela- 
noma cell line generated by our laboratory. Colo-205 and JY express 
HLA-A2. COS-7 cells were provided by Dr. B. Seed, Massachusetts 
General Hospital (Boston, Massachusetts). 
MAbs and Flow Cytometry 
Control IgG, anti-CD3 (Leu 4 MAb), anti-CD18 (L130 MAb), anti- 
CD8~ (Leu 2 MAb), anti-CD56 (L185 MAb), anti-CD19 (Leu 12 MAb) 
and anti-CD14 (Leu M3 MAb) were provided by Becton Dickinson 
Immunocytometry Systems. CyChrome-conjugated anti-CD3 was 
purchased from Pharmingen (San Diego, California). Anti-phospho- 
tyrosine MAb (4G10) was purchased from Upstate Biotechnology, 
Incorporated (Lake Placid, New York). Anti-HLA-A2 MAb was puri- 
fied from MA2.1 hybridoma obtained from ATCC (McMichael et al., 
1980). F(ab')2 fragments were prepared by digesting DX11 MAb 
(IgG1) and anti-CD18 (IgG1) with immobilized pepsin (10 mg IgG in 
10 ml of 0.2 M sodium citrate, 0.15 M NaCI buffer [pH 3.5], with 2.5 
ml immobilized pepsin for 2 hr at 37°C) (Pierce, Rockford, Illinois), 
and afterwards removing residual intact MAb by protein A affinity 
chromatography. Purity of the F(ab')2 fragments were determined 
by SDS-PAGE. Methods of immunofluorescent staining and flow 
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cytometry have been described previously (Lanier and Recktenwald, 
1991). Lymphocytes and monocytes were identified by their charac- 
teristic forward and right angle light scatter properties, as described 
previously (Lanier and Recktenwald, 1991). 
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Figure 6. Adhesion of DNAM-1 to Colo-205 
51Cr-labeled Colo-205 cell bound adherent COS-7 cells transfected 
with DNAM-1 cDNA and the binding was specifically blocked by 
the DX11 MAb. DX11 MAb was added to assay at 5 t~g/ml. ~lCr- 
labeled Colo-205 cells did not bind to COS-7 cells transfected with 
control gene (CD94) nor to untransfected COS.-7 cells (data not 
shown). 
CTL and NK Clones 
CTL and NK clones were established from peripheral blood of 
healthy donors as described (Phillips et al., 1991). In brief, PBMCs 
(Stanford Blood Center, Stanford, California) were isolated by Ficoll- 
Hypaque centrifugation. CD3" T cell clones or CD3 CD56 ~ NK were 
cloned by flow cytometry and cultured using the conditions de- 
scribed previously (Yssel et al., 1984). AIIoantigen (HLA-A2)-specific 
CTL clones were established from by mixed lymphocyte cultures 
using an HLA-A2- EBV-transformed B lymphoblastoid cell line, JY, 
as the stimulator and PBMCs from HLA-A2 donors as responders, 
as described (Yssel et al., 1984; Phillips et al., 1991). 
Cytotoxicity Assay 
Cell lines were labeled with 51Cr and used as targets in a 4 hr radioiso- 
tope release assay, as described (Lanier et al., 1983). Data are ex- 
pressed as the means of triplicate cultures and the spontaneous 
radioisotope release was typically < 10% of total 51Cr release. Pere- 
cent cytolysis was calculated as: 
cpm specific S'Cr release cpm spontaneous release 
× 100 
cpm total SlCr release cpm spontaneous release 
Lymphokine Assay 
CTL clones (1 ~ 10 s) were incubated with 1 × 105 irradiated Colo- 
205 or JY cells in 200 i~1 medium in U-bottomed 96-well plates 
(Becton Dickinson Labware, Lincoln Park, New Jersey) for 18 hr in 
the presence of the indicated MAbs (each at a final concentration 
of 10 /~g/ml). Supernatants were harvested and lymphokines were 
measured by enzyme-linked immunosorbent assay, as described 
(Chretien et al., 1989). 
Protein Purification and Sequencing 
PMBCs (2 ~: 10 ~°) were lysed in 200 ml of lysis buffer (50 mM Tris, 
150 mM NaCI [pH 8.0]) containing 1% NP-40 and protease inhibitors 
(1 mM PMSF and 20 Kallikrein inhibitor U/ml aprotinin). After removal 
of nuclei by centrifugation, the sample was incubated with 40 ml 
ConA Sepharose (Pharmacia, Uppsala, Sweden). Glycoproteins 
were eluted with lysis buffer containing 0.5 M ~-methyl-mannopyra- 
noside and were passed through a column containing 10 ml of 
Sepharose CNBr (Sigma, St. Louis, Missouri) coupled to a control 
murine IgG1 MAb. DNAM-1 glycoproteins were then isolated by 
using a column containing 25 ml of Sepharose covalently coupled 
to the DXl 1 MAb (2 mg DXl 1 MAb/ml Sepharose beads) and were 
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eluted with 50 ml of 50 mM diethylamine (pH >11.5). The sample 
was concentrated to a final volume of 40 t~l by using a Centricon- 
30 (Amicon, Incorporated, Beverly, Massachusetts). 2× Laemmli 
buffer was added and the proteins were separated by SDS-PAGE 
using 7% acrylamide gels (Bio-Rad, Richmond, California) and blot- 
ted onto polyvinylidene diflueride membranes (ProBIott, Applied 
Biosystems, Foster City, California). The membrane was stained 
with Coomassie blue (Bio-Rad) or Ponceau S (Sigma). Membrane 
fragments containing the DNAM-1 protein were subjected to direct 
N-terminal sequencing at our institution or digested with trypsin for 
sequence determination of internal peptides at the Harvard Micro- 
sequencing Facility (Cambridge, Massachusetts). Digested pep- 
tides were separated by reverse phase high pressure liquid chroma- 
tography and sequencing was done with an Applied Biosystems 
476A gas phase sequencer. 
cDNA Cloning 
Primary polymerase chain reaction (PCR) was performed with a 
sense degenerative primer encoding the peptide EEVLWHT (an 
N-terminal peptide fragment) and an antisense degenerative primer 
encoding the peptide QQDSlA (an internal peptide fragment) using 
a human ThO T cell clone (MOT81) cDNA plasmid library as the 
template. Using this primary PCR product as the template, a second 
PCR was performed with a degenerative sense primer encoding 
the peptide PFAENM (another N-terminal peptide fragment) and the 
same antisense primer. A 100 bp PCR product generated from the 
second PCR specifically hybridized with a 32P-radiolabeled oli- 
gonucleotide probe 5'-TTTGCIGAIAACATGTCCCTIGAITGTGTITA 
CCC-3' (I indicates inosine) encoding the peptide FAENMSLECVYP 
in the N-terminal peptide fragment. Plasmid clones (2 × 108) from 
the Th0 cDNA library were seeded into three 96-well plates and 
wells were screened by PCR for presence of the 100 bp DNAM-1 
cDNA fragment. We detected two positive wells and the clones in 
these wells were screened by a standard colony hybridization 
method using the 32P-radiolabeled 100 bp fragment as a probe. Two 
positive clones containing the same cDNA insert of 2.7 kb (plasmid 
LL378) were isolated and sequenced. The DNAM-1 cDNA was sub- 
cloned into the pMET7 expression vector and transfected into COS- 
7 cells using DEAE-dextran by the technique described previously 
(Aruffo and Seed, 1987). Transfectants were stained by immunofluo- 
rescence and analyzed by flow cytometry. 
Biochemistry 
Cells were labeled with 1251 using lactoperoxidase and glucose oxi- 
dase and lysed in Tris-buffered saline (50 mM Tris, 15 mM NaCI, 
[pH 8.0]) containing 1% NP-40, protease inhibitors (1 mM PMSF and 
20 Kallikrein inhibitor U/ml aprotinin), and phosphatase inhibitors (1 
mM EGTA, 10 mM NaF, 1 mM Na4P2OT, 0.1 mM I~-glycerophosphate, 
1 mM Na3VO4). DNAM-1 glycoproteins were immunoprecipitated 
using the methods described previously (Lanier et al., 1988) and 
treated with N-glycosidase F (Boehringer Mannheim Corporation, 
Indianapolis, Indiana) using the conditions recommended by the 
manufactures. Samples were analyzed by SDS-PAGE. 
For the analysis of DNAM-1 phosphorylation, 5 :< 10 ~ HLA-A2- 
specific CTL were incubated with 1 x 106 P815 cells and DX11 
MAb in a total volume of 100 i~1 tissue culture medium (RPMI-1640 
containing 10% fetal calf serum) in U-bottomed 96-weU plates. At 
various times, the cell mixture was centrifuged, supernatants dis- 
carded, and the cells were solublized in 1% NP-40 Tris-buffered 
saline (pH 8.0) with phosphatase and protease inhibitors. Lysates 
from 3 × 10 ~ CTL were immunoprecipitated with the indicated MAbs, 
as described (Lanier et al., 1988), and proteins were resolved by 
SDS-PAGE. Immunoprecipitates were transferred (100 V, 1 hr in 25 
mM Tris, 192 mM glycine, 20% methanol) to polyvinylidene difluoride 
membranes (Immobilon-P, Millipore). Membranes were incubated 
overnight in Tris-buffered saline containing 0.5% Tween 20 and 
MgCI2 (TBST) and 10% nonfat dry milk and then incubated with 
fluorescein isothiocyanate (FITC)-conjugated DX11 MAb (1 ;~g/ml 
in TBST with 10% nonfat dried milk) for 2 hr at room temperature. 
Proteins were detected by using horseradish peroxidase- 
conjugated sheep anti-FITC (Amersham, Arlington Heights, Illinois) 
and developed with SuperSignal CL-horseradish peroxidase Sub- 
strate (Pierce, Rockford, Illinois). Chemiluminescence was detected 
by autoradiograph. 
Cell Adhesion Assay 
COS-7 cells were transfected with DNAM-1 or CD94 (Chang et al., 
1995) cDNA, as described (Aruffo and Seed, 1987). ~lCr-labeled 
Colo-205 cells were added to 24-well plates containing adherent 
COS-7 cells expressing DNAM-1 or CD94 and incubated for 60 min 
at 37°C in the presence or absence of DX11 MAb (10 p.g/ml). After 
gently washing with tissue culture medium, cells were lysed in 10% 
Triton-X (in water) and radioactivity was measured. Results are ex- 
pressed as mean of triplicate cultures. 
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